Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease.
about
Hepatic radiation toxicity: avoidance and ameliorationIncorporating GSA-SPECT into CT-based dose-volume histograms for advanced hepatocellular carcinoma radiotherapyStereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study.Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinomaSurvival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy.The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities.Stem cell therapies for the treatment of radiation-induced normal tissue side effects.Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma.Radiotherapy for hepatocellular carcinoma: systematic review of radiobiology and modeling projections indicate reconsideration of its use.Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma.Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapyRadiation-associated liver injury.Integrative Metabolic Signatures for Hepatic Radiation Injury.Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma.RapidArc vs intensity-modulated radiation therapy for hepatocellular carcinoma: a comparative planning study.Reducing the probability of radiation-induced hepatic toxicity by changing the treatment modality from helical tomotherapy to fixed-beam intensity-modulated radiotherapyStereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumorsDetermination of the α/β ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinomaHedgehog signaling and radiation induced liver injury: a delicate balance.Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma.Identification of Biologically Effective Dose-Volumetric Parameters That Predict Radiation-Induced Hepatic Toxicity in Patients Treated With Helical Tomotherapy for Unresectable Locally Advanced Hepatocellular Carcinoma.High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicitiesLiver function after irradiation based on computed tomographic portal vein perfusion imagingRadiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parametersChallenge and hope in radiotherapy of hepatocellular carcinomaRole of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results.Biomarker studies on radiotherapy to hepatocellular carcinoma.Role of external beam radiation therapy in management of hepatocellular carcinoma.Radiation-induced liver disease: current understanding and future perspectivesA Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus.Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve.The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma.Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma.Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry.Modeling of Normal Tissue Complications Using Imaging and Biomarkers After Radiation Therapy for Hepatocellular Carcinoma.Strategies for prediction and mitigation of radiation-induced liver toxicity.Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma.Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity.
P2860
Q27023687-D3F1F063-DCDC-4239-AFEC-EF04094E1277Q27030865-C5DAD04B-B1E9-48C9-A07E-404A3A3D44B5Q33257944-666F6EC4-FE39-43E9-8CFB-5D6BBE19F97BQ33593108-1FEEA7DC-D70F-4B18-8971-3A58E779B893Q33699349-0F6E8BC4-708A-4BD4-8908-8C1910CA94D6Q33746887-BD85998C-0122-4DE2-9ADD-2B669735A906Q33768112-9D0E3ABD-DEEC-4E4D-9ECD-33E7B8D54BA9Q33818431-DB0FE5C9-CBB2-4135-B5DB-A1C238C541E8Q34615726-9D116C77-307F-413D-AEEB-85687DE90DE3Q35051831-F4A4B567-9B48-4C28-9E11-4E429BEAD1A5Q35111353-488B5149-FD97-4A82-B4C4-059F5EBE9A48Q35297759-3C38C192-A287-44BC-B24B-F63D9FF0B421Q35654209-B0D01213-D680-48C7-80C4-758ED364ED81Q36074220-A45FA0F8-882C-4E76-AC3E-AF841A56D082Q36225933-6CAE984D-4B01-48D8-8350-AF0B3A1820ABQ36326035-864703F0-8751-4DC3-9082-632B1ACDCF5DQ36545343-205D71C9-F7BC-42CB-9E20-C967123C2A04Q36570322-C7DB8B08-68B0-4D0B-9E42-B25143A030FFQ36811589-F113E294-D2C7-47F2-B6B9-C8D11B036D67Q36955776-01CE58F4-0676-4FB9-BCFE-58A9F49905C5Q37013991-73C53806-3101-49DF-BDDF-421D63A67839Q37059598-272A1D08-CFEE-46FC-A518-166CA5F701FDQ37176354-A4236699-699B-40D4-848B-64EF957EF855Q37269624-913B7DAF-B633-4673-8037-0A57E2FCE2A0Q37272492-BC6E6688-255C-4F5F-9E43-6FCA29E9FC2FQ37277060-A966798B-7FAE-4ADA-88E2-62619F31DD01Q37400936-F6537E62-42CD-49E7-9ED4-91F4B0296BADQ37487162-6C4705A6-089D-43BA-BC78-5B0DB1B3D9B2Q38083433-D5791E6C-47B8-43EE-8B82-9F2D944B6558Q38371619-6184B7DE-596C-407A-9435-1817140DF9B1Q38654063-14955039-A1F4-47DD-92CF-757F69664A80Q38665389-BA44C397-D3B7-4BB9-904D-4C1622A9979BQ38677020-8BB8FCF6-6363-4B06-BA6D-27688B200BB2Q43865857-71D3488E-0B53-4724-8078-258BE9499E08Q43897398-5D6C98CA-1CA2-4A67-8380-9CA878ADA5A1Q47665576-B81E6256-C2C0-4FA6-B7E1-426F503ACEC4Q49896456-94DB9C64-1FF6-4CF6-9C9A-7379645BAF23Q50061872-F5940D07-4D06-4C44-979C-3F1B0ED090B3Q51778319-3AD16316-5466-4218-AC5A-B21C965D8AD6Q53118337-3C371B4E-02D5-416A-ACF0-3976B9AA127D
P2860
Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Biologic susceptibility of hep ...... diation-induced liver disease.
@en
Biologic susceptibility of hep ...... diation-induced liver disease.
@nl
type
label
Biologic susceptibility of hep ...... diation-induced liver disease.
@en
Biologic susceptibility of hep ...... diation-induced liver disease.
@nl
prefLabel
Biologic susceptibility of hep ...... diation-induced liver disease.
@en
Biologic susceptibility of hep ...... diation-induced liver disease.
@nl
P2093
P1476
Biologic susceptibility of hep ...... diation-induced liver disease.
@en
P2093
Gwo-Jen Jan
Hua-Shan Liu
James Jer-Min Jian
Jason Chia-Hsien Cheng
Jian-Kuen Wu
Juei-Low Sung
Patricia Chiao-Tzu Lee
Yu-Mong Lin
P304
P356
10.1016/J.IJROBP.2004.05.048
P407
P577
2004-12-01T00:00:00Z